China Railway Group Ltd (CRGL) is an integrated construction company. It offers construction-related services, including infrastructure construction, survey, design and consulting services, and engineering equipment and component manufacturing. It also ventures into property development, asset operation, resource utilization, financial and merchandise trading, and emerging businesses. CRGL designs and constructs bridges, tunnels, and electrified railways, and the design and manufacturing of bridge steel structures and turnouts in China.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

CRGL has established a comprehensive scientific and technological innovation platform system, which includes national laboratories, postdoctoral workstations, and various research centers. In 2025, the company undertook 12 key national research and development projects, participated in projects funded by the National Natural Science Foundation of China, and initiated major special projects based on recommendations from academicians. The company also focused on deploying cutting-edge technologies to build a generational advantage. The company has three national laboratories, 10 postdoctoral workstations, a national-local joint research center, 61 provincial and ministerial R&D centers, 21 nationally recognized enterprise technology centers, and 142 provincially and ministerially recognized enterprise technology centers. The company was granted 8,540 patents in 2025, including 3,624 invention patents and 194 overseas patents. In FY2025, the company held 48,029 valid patents, including 15,725 invention patents and 1,078 overseas patents. In FY2025, the company spent CNY22.4 billion on R&D, which as a percentage of total revenue stood at 2.1%.